Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Disc Medicine Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company pioneering novel therapies for hematologic disorders through innovative research in iron metabolism and red blood cell biology. This page serves as the definitive source for verified corporate developments, research milestones, and regulatory updates.
Investors and researchers will find timely updates on clinical trials for lead candidates including bitopertin (targeting erythropoietic protoporphyria) and DISC-0974 (for anemia management). Our curated news collection covers essential updates, partnership announcements, and scientific presentations without speculative commentary.
Key content categories include phase trial results, FDA communications, intellectual property developments, and peer-reviewed research findings. All materials are vetted for accuracy and relevance to therapeutic advancements in hematology.
Bookmark this page for streamlined access to IRON's latest progress in developing first-in-class therapies that address unmet needs in iron-related disorders. Check regularly for objective updates on pipeline candidates and corporate strategy.
Disc Medicine (NASDAQ:IRON) announces a virtual KOL investor event on May 9, 2025, focusing on anemia of myelofibrosis (MF) and its treatment landscape. The webinar will feature leading experts including:
- Dr. Aaron Gerds from Cleveland Clinic
- Dr. Prithviraj Bose from MD Anderson Cancer Center
The event will cover MF anemia's epidemiology, pathogenesis, and patient impact. Disc's leadership will present clinical data for DISC-0974, including Phase 1b trial results from the 2024 ASH meeting and ongoing Phase 2 trial design. They will discuss the expected market opportunity and timeline for interim Phase 2 data readout in 2025.
The webinar starts at 1:00 PM ET / 10:00 AM PT, with a replay available for 90 days on Disc's website.
Disc Medicine (NASDAQ:IRON) reported its Q4 and full year 2024 financial results, highlighting significant progress across its pipeline. The company ended 2024 with $490 million in cash and secured additional funding through a January 2025 public offering, extending operations into 2028.
Key developments include plans for bitopertin NDA submission in H2 2025 for erythropoietic protoporphyria (EPP) through accelerated approval pathway, with the APOLLO confirmatory trial set to begin mid-2025. The company presented positive data from DISC-0974's Phase 1b trial in myelofibrosis anemia and non-dialysis-dependent chronic kidney disease patients.
Financial results show R&D expenses increased to $96.7 million in 2024 from $69.3 million in 2023, while net loss widened to $109.4 million from $76.4 million. SG&A expenses rose to $33.0 million from $21.9 million, reflecting increased headcount and commercialization preparation efforts.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in hematologic disease treatments, has announced its participation in four major upcoming investor conferences in March 2025.
The company will deliver presentations at:
- TD Cowen 45th Annual Health Care Conference in Boston (March 5th, 9:10 a.m. ET)
- Leerink Global Healthcare Conference in Miami (March 10th, 2:20 p.m. ET)
- Barclays 27th Annual Global Healthcare Conference in Miami (March 13th, 9:30 a.m. ET)
- Jefferies Biotech on the Beach Summit in Miami (March 11th)
Live webcasts of the presentations and fireside chats will be accessible through Disc Medicine's investor relations website, with archived replays available post-event.
Disc Medicine (NASDAQ: IRON) has announced the pricing of its upsized public offering, consisting of 3,918,182 shares of common stock at $55.00 per share and pre-funded warrants to purchase 181,818 shares at $54.9999 per warrant. The offering is expected to generate approximately $225.5 million in gross proceeds before deducting expenses.
The company has granted underwriters a 30-day option to purchase up to an additional $33.825 million of shares. The offering is expected to close on January 24, 2025. Proceeds will fund research and clinical development, support potential commercialization of bitopertin for EPP and XLP, and provide working capital.
Jefferies, Leerink Partners, Stifel, and Cantor are serving as joint book-running managers, with BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, and H.C. Wainwright & Co. as co-managers.
Disc Medicine (NASDAQ: IRON) has announced a proposed public offering of $200.0 million of common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to an additional $30.0 million of shares. The proceeds will fund research and clinical development of product candidates, support potential commercialization of bitopertin for EPP and XLP, and provide working capital.
The offering is being managed by joint book-runners Jefferies, Leerink Partners, Stifel, and Cantor. The securities will be offered through an automatic shelf registration statement previously filed with the SEC. The completion, size, and terms of the offering are subject to market conditions.
Disc Medicine (NASDAQ:IRON) has received positive feedback from its Type C meeting with the FDA regarding bitopertin for Erythropoietic Protoporphyria (EPP) treatment. The company plans to submit a New Drug Application (NDA) in H2 2025 under the accelerated approval pathway, using protoporphyrin IX (PPIX) reduction as the surrogate endpoint.
The FDA meeting resulted in alignment on the APOLLO post-marketing confirmatory trial design, set to begin by mid-2025. The trial will feature co-primary endpoints: average monthly time in sunlight without pain and percent change in whole blood metal-free PPIX after 6 months of treatment. The study will be double-blind, placebo-controlled with approximately 150 patients aged 12+ randomized 1:1, including sites in the US, Canada, Europe, and Australia.
Disc Medicine (NASDAQ:IRON) has announced a conference call scheduled for Tuesday, January 21, at 8:00 am EST to discuss feedback from its Type C meeting with the FDA regarding bitopertin in Erythropoietic Protoporphyria (EPP). The company, which focuses on developing treatments for serious hematologic diseases, will host the discussion to share insights from their regulatory interaction.
Interested participants can register for the event through the Events and Presentations section of Disc Medicine's investor relations website. This meeting represents a significant step in the development process for bitopertin as a potential treatment for EPP patients.
Disc Medicine (NASDAQ:IRON) has announced an inducement equity award for a new employee, effective January 16, 2025. The award consists of two components: (1) an option to purchase 35,000 shares of common stock at the January 16, 2025 closing price, and (2) a restricted stock unit (RSU) award for 23,333 shares.
The stock option has a ten-year term with 25% vesting on January 16, 2026, and the remaining vesting monthly over 36 months. The RSU award vests in equal installments over four years. The Compensation Committee approved this award as an employment inducement under Nasdaq Rule 5635(c)(4), outside the company's regular stock incentive plan but under similar terms.
Disc Medicine (NASDAQ:IRON) outlined its achievements and strategic priorities for 2025, highlighting significant progress across its hematology portfolio. Following positive phase 2 results for bitopertin in EPP, the company will discuss NDA submission plans under potential accelerated approval in Q1 2025.
Key upcoming milestones include initial data from phase 2 study of DISC-0974 in myelofibrosis anemia and higher dose data from phase 1b study in CKD anemia, both expected H2 2025. The company plans to initiate a phase 2 study of DISC-3405 in polycythemia vera in H1 2025.
The company strengthened its balance sheet through a $178 million equity offering and secured debt facility, providing cash runway into 2027. 2024 achievements included positive FDA end-of-phase 2 meeting for bitopertin, successful phase 2 AURORA and BEACON studies, and encouraging results from DISC-0974 trials.
Disc Medicine (NASDAQ:IRON) presented positive clinical data across its portfolio at the ASH 2024 Annual Meeting, featuring 8 posters and complete results from multiple trials. Key highlights include:
- Updates from BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP) showing significant PPIX reduction and improved sunlight tolerance
- Complete results from Phase 1b trial of DISC-0974 in myelofibrosis anemia, supporting advancement to Phase 2
- Phase 1 SAD/MAD trial data of DISC-3405 in healthy volunteers demonstrating sustained serum iron reduction and good tolerability
The company also presented preclinical data supporting potential expansion into new indications and a real-world patient survey highlighting EPP disease burden.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
